Jon Congleton - 09 Feb 2023 Form 3 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Executive Officer, Director
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
09 Feb 2023
Net transactions value
$0
Form type
3
Filing time
09 Feb 2023, 18:52:38 UTC
Next filing
21 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MLYS Common Stock 1,038,318 09 Feb 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MLYS Stock Option 09 Feb 2023 Common Stock 24,082 $0.5300 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

Remarks:

EXHIBIT LIST: EX-24 Jon Congleton POA